BiotechTube

Anplag Tab. 100mg bid + Anplag Tab. 100mg tid

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Peripheral Artery Disease, PAD

Conditions

Peripheral Artery Disease, PAD

Trial Timeline

Oct 11, 2018 → Mar 5, 2020

NCT ID
NCT03509922

About Anplag Tab. 100mg bid + Anplag Tab. 100mg tid

Anplag Tab. 100mg bid + Anplag Tab. 100mg tid is a approved stage product being developed by Yuhan for Peripheral Artery Disease, PAD. The current trial status is completed. This product is registered under clinical trial identifier NCT03509922. Target conditions include Peripheral Artery Disease, PAD.

What happened to similar drugs?

19 of 20 similar drugs in Peripheral Artery Disease, PAD were approved

Approved (19) Terminated (4) Active (1)
✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
✅QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved
✅Mecobalamin IV Injection + Mecobalamin IM injection + Mecobalamin IV or IM injectionEisaiApproved
✅Ticagrelor + clopidogrelAstraZenecaApproved
✅Gabapentin/B-complex + PregabalinMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03509922ApprovedCompleted

Competing Products

20 competing products in Peripheral Artery Disease, PAD

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
18
LY3857210 + PlaceboEli LillyPhase 2
35
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
43
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 3
40
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
29
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
35
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Valemetostat TosylateDaiichi SankyoPhase 2
39
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
27
QutenzaAstellas PharmaPre-clinical
26
QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
43
Qutenza exposureAstellas PharmaPre-clinical
26
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43
Capsaicin 8% + PlaceboAstellas PharmaPhase 3
40